Tag: #SARS-CoV-2
Articles tagged with #SARS-CoV-2
What is ACE-2 Receptor, How it is Connected with SARS-CoV-2, and How Do We Know SARS-CoV-2 Uses ACE-2 Receptor for Entering the Host Cell?
Long been coronavirus, the virus that causes CVID-19, has been a hot and ramping issue all over the world. Though some international biopharmaceuticals like …
January Timeline of Coronavirus
No one would have suspect that this coronavirus, which causes disease COVID-19, will be so much devastating and affect the globe in all the possible ways it …
Seems Like COVID-19 Vaccine will be Ready by the End of 2020
Earlier in April 2020, researchers from the University of Oxford at the Oxford COVID-19 Vaccine Centre had initiated a phase I trial of their COVID-19 vaccine …
Bio-Tech Company ‘Moderna’ Attaining New Height for COVID-19 Cure Vaccine
Colorized scanning electron micrograph of a cell heavily infected with SARS-CoV-2 virus particles (yellow), isolated from a patient sample. The black area in …
COVID-19 Vaccine Update from a China-Based Biotech Company is Promising
Whole world is in desperate need of the COVID-19 vaccine/antidote and this seems evident especially in this situation where the number of confirmed cases hits …
Killing Coronavirus by 'Air Filter' Could be the Best Alternative for Ongoing Worst Situation
Device for virus experiment. Photographs show the device details (left) and one of the two filters using folded Ni foam (right). On December 31, 2019, …
Researchers Found Neuropilin-1 Facilitates SARS-CoV-2 Infectivity
RNA viruses such as SARS-CoV-2 have a remarkable ability to adapt to their host environment by generating adaptive mutations in a short period.
Gilead Announced Results from Phase III Trial of Remdesivir
On June 01, 2020, Gilead made and announcement, through a press release, about the results from its phase III SIMPLE trial of remdesivir in human patients.
Host Factor Determines the Severity of COVID-19, not the Varied Strain
Researchers analyzed the clinical, molecular, and immunological data from 326 confirmed cases of COVID-19 in Shanghai and discovered two different SARS-CoV-2 strains within their patient cohort but that viral variations did not significantly affect the patient outcomes.
Here is the Most Detailed 3D Representation of SARS-COV-2
The coronavirus RNA molecule is one of the largest amongst all RNA viruses at 30,000 'letters' long, which is about twice the size of the influenza A genome, but still 100,000 times smaller than the human genome (over 3 billion 'letters' long).
Yes, Coronavirus is Mutating but You don’t Need to Panic
Researchers have identified 6,822 mutations of SARS-CoV-2 across a global dataset among which 273 mutations have occurred repeatedly and independently.
Another COVID-19 Vaccine Enter in Phase 1/2 of Clinical Trial
The Clinical trial started on May 25, 2020. First volunteer participants are already enrolled. Estimated Primary Completion Date is December 31, 2020, and Estimated Study Completion Date July 31, 2021.
A Prominent Technique to Detect SARS-CoV-2: Real Time RT-PCR(rRT-PCR)
Real-time RT-PCR has risen to become the benchmark technology for the detection and/or comparison of RNA levels for several reasons...
Phase II/III of COVID-19 Vaccine is About to Begin at Oxford COVID-19 Vaccine Centre
The University of Oxford, Oxford COVID-19 Vaccine Centre's researchers have already begun recruiting human volunteers for the next phase in human trials of a COVID-19 vaccine trial in humans.
COVID-19: Another Potent Antiviral Drug in the List
A team of researchers has recently found that an antiviral drug can help speed up the recovery of COVID-19 patients. The international team was led by Dr. Eleanor Fish, Scientist Emeritus at the Toronto General Hospital Research Institute, University Health Network (UHN), and professor at the University of Toronto's Department of Immunology.
Antibody, STI-1499, Successfully Inhibited the SARS-CoV-2 Infection, In Vitro
In preclinical experiments, in vitro, Sorrento Therapeutics researchers found that a potent Anti-SARS-CoV-2 antibody, STI-1499, demonstrated a 100% inhibition of SARS-CoV-2 virus infection and they experimentally observed this inhibition at a very low antibody concentration.
Green Light from Health Canada for the First Clinical trial for Potential COVID-19 Vaccine
On May 16, 2020, the Canadian health agency, Health Canada, has given approved the first Canadian clinical trial for a potential COVID-19. Prime Minister Justin Trudeau announced Saturday (May 16, 2020) that the Canadian Center for Vaccinology at Dalhousie University has been given the green light by the federal health authority to begin clinical trials of the vaccine candidate.
COVID-19: Why it is Taking So Much Time for Designing Drugs?
It has been claimed that the coronavirus has about 30 proteins which are small compared to human cells (humans have more than 20,000). Due to this small number of proteins in a cell, coronavirus can’t reproduce on their own.
COVID-19: Researchers at QCRG are Working Differently
A team at Quantitative Biosciences Institute Coronavirus Research Group (QCRG) is working to understand the plan of coronavirus so they can particularly treat them...
COVID-19: Coronavirus is Replicating in a Peculiar way, Scientist Knows How
Once viruses get inside the cell they use the resources and mechanism of the cell producing thousands of viruses that will eventually lead to the death of the cell. This process is simply hijacking the cell and turning it into a production factory of coronavirus. It has been claimed that the coronavirus has about 30 proteins which is small compared to human cells (humans have more than 20,000). Due to this small number of proteins in a cell coronavirus can’t reproduce on their own and to get around with this limited set of tools and they cleverly turn the human body against itself.